SKS

Tarkett launches non-PVC resilient flooring collection with superior performance

Retrieved on: 
星期四, 四月 18, 2024
Nature, SKS, Collection, Carbon, Tarkett, LVT, Wood, Recycling, Organization

SOLON, Ohio, April 18, 2024 /PRNewswire/ -- Global flooring manufacturer Tarkett has launched a non-PVC plank and tile flooring collection, evidence of the company's holistic approach to helping organizations meet their sustainability goals.

Key Points: 
  • SOLON, Ohio, April 18, 2024 /PRNewswire/ -- Global flooring manufacturer Tarkett has launched a non-PVC plank and tile flooring collection, evidence of the company's holistic approach to helping organizations meet their sustainability goals.
  • The collection, Collective Pursuit™, is a high-performance solution that rivals luxury vinyl tile in dimensional stability, impact resistance and ease of maintenance.
  • It is the first collection of its kind from Tarkett North America.
  • "At Tarkett, we have listened to market demands and innovated to deliver solutions that perform as well as they inspire.

DermBiont Announces 2024 Development Pipeline Update for its First-in-Class Targeted Topical Therapeutics for Seborrheic Keratoses, Basal Cell Carcinomas, and Melasma

Retrieved on: 
星期四, 二月 22, 2024
Health, Other Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Therapy, Skin cancer, Neoplasm, Recurrence, Melasma, Scar, Toxicity, Melanocyte, FDA, SKS, Skin, Dermatoscopy, BCC, Entrepreneurship, Hyperpigmentation, Risk, Epidermis, Safety, PLA, Patient, Carcinoma, Laser, Medical imaging

DermBiont currently anticipates that data will be available in Q3 2024.

Key Points: 
  • DermBiont currently anticipates that data will be available in Q3 2024.
  • SKs: DermBiont expects to report data from its CT-213 Phase 2b clinical trial of SM-020 gel 1.0% in Q3 2024.
  • BCCs and SCCISs: DermBiont expects to initiate its CT-217 Phase 2a clinical trial in Q1 2024 and report data in Q3 2024.
  • Melasma: DermBiont anticipates enrolling the first patient in its randomized, observer-blinded, vehicle-controlled CT-214 Phase 2b trial of SM-030 in 138 subjects with melasma in Q2 2024.

DermBiont Announces First Close of $35.2 Million in a Series B Financing to Advance First-in-Class Targeted Topical Dermatological Therapeutics

Retrieved on: 
星期二, 十月 24, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Olive, FDA, Viking Global Investors, Food, Hyperpigmentation, Therapy, PKC, Skin, DPN, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Laser, Melasma, Physician, Recurrence, Venture round, Civilization, Dermatology, Safety, SKS, SK, Series, Patient, AKT, Dermatosis papulosa nigra, Pharmaceutical industry, Dietary supplement

DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced a $35.2 million Series B financing, including a $27.1 million Series B first close and $8.1 million in converting outstanding notes.

Key Points: 
  • DermBiont, a clinical-stage biotechnology company that is advancing targeted topical therapeutics for the treatment of dermatological indications, today announced a $35.2 million Series B financing, including a $27.1 million Series B first close and $8.1 million in converting outstanding notes.
  • The Series B was led by new institutional investor, Double Point Ventures, and includes continued support from Viking Global Investors, Civilization Ventures, Olive Tree Capital, and others.
  • These products prioritize the patient experience by addressing the root cause of both diseases with excellent efficacy, safety, and tolerability.
  • Phase 2b open label clinical trial in 10 subjects with DPN (Dermatosis Papulosa Nigra) treated with SM-020 gel 1% twice daily for 28 days.

SmartX Introduces SKS 1.0 for Rapid Deployment of Production-Ready Kubernetes Clusters

Retrieved on: 
星期二, 六月 6, 2023
Component, VM, Alauda, Policy, CNCF, VMS, Automation, SKS, Cluster, HCI, Ecosystem, Contour, Video game, Prometheus, Kubernetes

BEIJING, June 6, 2023 /PRNewswire/ -- SmartX today releases SKS 1.0 , to help I&O teams easily deploy and manage production-ready Kubernetes clusters.

Key Points: 
  • BEIJING, June 6, 2023 /PRNewswire/ -- SmartX today releases SKS 1.0 , to help I&O teams easily deploy and manage production-ready Kubernetes clusters.
  • SKS preloads commonly-used Kubernetes addons and integrates industry-leading SmartX hyper-converged product components (including virtualization, distributed storage, networking and security, etc.
  • To address these challenges, SmartX has released SKS 1.0, a one-stop solution for building production-ready Kubernetes clusters with necessary resources.
  • Automate and standardize full lifecycle management of Kubernetes clusters, including rapid cluster scaling, node replacement, and upgrade/rollback.

SmartX Introduces SKS 1.0 for Rapid Deployment of Production-Ready Kubernetes Clusters

Retrieved on: 
星期二, 六月 6, 2023
Component, VM, Alauda, Policy, CNCF, VMS, Automation, SKS, Cluster, HCI, Ecosystem, Contour, Video game, Prometheus, Kubernetes

BEIJING, June 6, 2023 /PRNewswire/ -- SmartX today releases SKS 1.0 , to help I&O teams easily deploy and manage production-ready Kubernetes clusters.

Key Points: 
  • BEIJING, June 6, 2023 /PRNewswire/ -- SmartX today releases SKS 1.0 , to help I&O teams easily deploy and manage production-ready Kubernetes clusters.
  • SKS preloads commonly-used Kubernetes addons and integrates industry-leading SmartX hyper-converged product components (including virtualization, distributed storage, networking and security, etc.
  • To address these challenges, SmartX has released SKS 1.0, a one-stop solution for building production-ready Kubernetes clusters with necessary resources.
  • Automate and standardize full lifecycle management of Kubernetes clusters, including rapid cluster scaling, node replacement, and upgrade/rollback.

EQS-News: Oldenburgische Landesbank AG: OLB successfully completes first synthetic risk transfer

Retrieved on: 
星期六, 四月 15, 2023
SKS, Oldenburgische Landesbank, UniCredit, Degussa Bank, Bank, Common equity, SK Group, CET, OLB

Oldenburgische Landesbank AG (OLB) successfully completed its first synthetic risk transfer.

Key Points: 
  • Oldenburgische Landesbank AG (OLB) successfully completed its first synthetic risk transfer.
  • Under the transaction, potential default risks were transferred to investors, but the actual contractual relationship between OLB and its borrowers remained unaffected.
  • "With our first synthetic risk transfer, we have strengthened our balance sheet and will be able to manage it even more efficiently in the future," says Dr Rainer Polster, Chief Financial Officer of OLB.
  • OLB was advised by Clifford Chance, Iconicchain, UniCredit and SKS Group regarding the transaction.

DermBiont Presents Positive Phase 2 Trial Data Treating Seborrheic Keratosis with SM-020 Topical Gel at American Academy of Dermatology Annual Meeting

Retrieved on: 
星期三, 三月 22, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, American Academy of Dermatology, Hypopigmentation, Therapy, SKS, Cryosurgery, Neoplasm, Food, Edema, Clinical trial, Scar, American Academy, Itch, Pain, Erythema, Patient, AKT, AAD, Risk, BID, Apoptosis, Hyperpigmentation, PLA, Entrepreneurship, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Skin, Safety, Casting, Pharmaceutical industry, Wood-plastic composite

SM-020 is a selective and potent AKT inhibitor applied by patients at home to their seborrheic keratoses (SK) lesions.

Key Points: 
  • SM-020 is a selective and potent AKT inhibitor applied by patients at home to their seborrheic keratoses (SK) lesions.
  • SKs are currently treated with ablative surgical procedures and there is currently no available topical therapy for these tumors.
  • DermBiont’s Phase 2 proof-of-concept, adaptive open-label trial tested SM-020 gel 0.1% and 1.0%, enrolling 35 subjects with 4 SK target lesions across seven treatment cohorts.
  • "We are pleased to have presented positive results from our Phase 2 adaptive, open-label trial with SM-020 at the prominent AAD annual meeting.

COMSovereign Issues Update Regarding Adjournment of Annual Meeting of Stockholders and Reminder to Vote

Retrieved on: 
星期三, 一月 18, 2023
Partner, Security (finance), Internet, Business, Telecommunication, LTIP, DragonWave, Annual Meetings of the International Monetary Fund and the World Bank Group, The, Shareholder, Opportunity, Annual, Telephone, SKS, Annual general meeting, Balance sheet, LTE Advanced, Software, New Year, Long-term incentive plan, Advantage, Sale, Letter, Innovation, The Company, Proxy, Auction, Internet service provider, Holding company, Management, Risk management, Fastback

TUCSON, Ariz., Jan. 18, 2023 /PRNewswire/ -- COMSovereign Holding Corp. (NASDAQ: COMS) ("COMSovereign" or the "Company"), a U.S.-based developer of 4G LTE Advanced and 5G Communication Systems and Solutions today issued the following update regarding its 2022 Annual Meeting of Shareholders:

Key Points: 
  • Stockholders that held stock on November 21, 2022 are eligible to vote at this Annual meeting.
  • No changes have been made in the proposals to be voted on by Stockholders at the Annual Meeting.
  • COMSovereign asks that all Stockholders vote their proxy, no matter how many shares they own.
  • Urgent Shareholder Voting at Our Upcoming 2023 Annual Meeting – On January 18, 2023, COMSovereign will hold its annual shareholder meeting.

Accenture to Acquire SKS Group, Strengthening its SAP® and Regulatory Capabilities for Banking Clients in Germany, Austria and Switzerland

Retrieved on: 
星期二, 一月 10, 2023
Technology, Finance, Consulting, Security, Banking, Professional Services, Software, Networks, Data Management, Risk, NYSE, SK Group, ARZ, SKS, Acquisition, Multimedia, SAP, Bank, Audit, Accenture

Accenture (NYSE: ACN) has agreed to acquire SKS Group, a consulting firm that helps banks across Germany, Austria and Switzerland modernize their technology infrastructure and address regulatory requirements using SAP S/4HANA® solutions.

Key Points: 
  • Accenture (NYSE: ACN) has agreed to acquire SKS Group, a consulting firm that helps banks across Germany, Austria and Switzerland modernize their technology infrastructure and address regulatory requirements using SAP S/4HANA® solutions.
  • View the full release here: https://www.businesswire.com/news/home/20230109005777/en/
    Accenture has agreed to acquire SKS Group, a consulting firm that helps banks across Germany, Austria and Switzerland modernize their technology infrastructure and address regulatory requirements using SAP S/4HANA® solutions.
  • With headquarters in Hochheim, Germany, SKS Group’s team of approximately 500 professionals will join Accenture Technology.
  • SKS Group also has an extensive suite of risk, regulatory services and compliance capabilities, including its observatory tool which maps regulatory requirements to help banks manage their reporting processes.

COMSovereign Issues New Year CEO Update Letter

Retrieved on: 
星期二, 一月 10, 2023
The Company, Long-term incentive plan, Software, Innovation, Annual general meeting, Business, LTIP, Partner, Letter, Opportunity, Telecommunication, SKS, Balance sheet, DragonWave, Shareholder, LTE Advanced, The, New Year, Sale, Management, Risk management, Holding company, Fastback

Since I last wrote to you, I have committed to become COMSovereign's CEO and President .

Key Points: 
  • Since I last wrote to you, I have committed to become COMSovereign's CEO and President .
  • The goal of this effort is to reduce costs, generate revenue and maximize their value of the Company's assets.
  • We continue to make important strides across our operations including significantly reduced headcount through the elimination of redundancies.
  • Urgent Shareholder Voting at Our Upcoming 2023 Annual Meeting – On January 18, 2023, COMSovereign will hold its annual shareholder meeting.